Adaptive Biotechnologies reported third-quarter 2026 revenue of $83.9 million, a 11% decrease from the prior year period but a 39% increase excluding Genentech Agreement revenue. The company achieved total profitability with adjusted EBITDA of $14.3 million and net income of $2.8 million. Management raised full-year MRD revenue guidance to a range of $276 million to $286 million, up from the previous estimate of $268 million to $278 million, reflecting 30% to 35% annual growth. The company also reported operating expenses of $84.4 million and cash reserves of $400.2 million as of September 30, 2026. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system for clinical diagnostics and therapeutics.
